Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

The cost of prescription drugs: a comparison of two countries.

Jick H, Wilson A.

Pharmacotherapy. 2012 Nov;32(11):967-9. doi: 10.1002/phar.1224. No abstract available.

PMID:
23124721
2.

Zero copayment for generic statins could save billions.

[No authors listed]

Manag Care. 2013 Mar;22(3):44. No abstract available.

3.

Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs.

Godman B, Schwabe U, Selke G, Wettermark B.

Pharmacoeconomics. 2009;27(5):435-8. doi: 10.2165/00019053-200927050-00010. No abstract available.

PMID:
19586083
4.

Encouraging generic use can yield significant savings.

Zimmerman C.

Find Brief. 2012 Nov;15(8):1-3.

PMID:
23213854
5.

Comparison of prescription drug costs in the United States and the United Kingdom, part 2: proton pump inhibitors.

Jick H, Wilson A, Wiggins P, Chamberlain DP.

Pharmacotherapy. 2012 Jun;32(6):489-92. doi: 10.1002/j.1875-9114.2012.01111.x. Epub 2012 Apr 17.

PMID:
22511180
6.

Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.

Fraeyman J, Verbelen M, Hens N, Van Hal G, De Loof H, Beutels P.

Appl Health Econ Health Policy. 2013 Oct;11(5):543-52. doi: 10.1007/s40258-013-0054-9.

PMID:
24062144
7.

Comparison of prescription drug costs in the United States and the United Kingdom, Part 1: statins.

Jick H, Wilson A, Wiggins P, Chamberlin DP.

Pharmacotherapy. 2012 Jan;32(1):1-6. doi: 10.1002/PHAR.1005.

PMID:
22392823
8.

How to lose a billion pounds.

Moon JC, Bogle RG.

Int J Clin Pract. 2007 Jan;61(1):2-3. No abstract available.

PMID:
17229170
9.

Getting better value from the NHS drug budget.

Moon JC, Flett AS, Godman BB, Grosso AM, Wierzbicki AS.

BMJ. 2010 Dec 17;341:c6449. doi: 10.1136/bmj.c6449. No abstract available.

PMID:
21169320
10.

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications.

Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi R, Kalaba M, Laius O, McGinn D, Samaluk V, Sermet C, Schwabe U, Teixeira I, Tilson L, Tulunay FC, Vlahović-Palčevski V, Wendykowska K, Wettermark B, Zara C, Gustafsson LL.

Expert Rev Pharmacoecon Outcomes Res. 2010 Dec;10(6):707-22. doi: 10.1586/erp.10.72.

PMID:
21155704
11.

Generic atorvastatin and health care costs.

Jackevicius CA, Chou MM, Ross JS, Shah ND, Krumholz HM.

N Engl J Med. 2012 Jan 19;366(3):201-4. doi: 10.1056/NEJMp1113112. Epub 2011 Dec 7. No abstract available.

12.

The impact of reference-pricing systems in Europe: a literature review and case studies.

Dylst P, Vulto A, Simoens S.

Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):729-37. doi: 10.1586/erp.11.70. Review.

PMID:
22098289
13.

In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.

Hoadley JF, Merrell K, Hargrave E, Summer L.

Health Aff (Millwood). 2012 Oct;31(10):2266-75. doi: 10.1377/hlthaff.2012.0019.

14.

The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.

Fraeyman J, Van Hal G, Godman B, Beutels P.

Expert Rev Pharmacoecon Outcomes Res. 2013 Feb;13(1):141-51. doi: 10.1586/erp.12.88.

PMID:
23402454
15.

Generic atorvastatin and health care costs.

Kennally WC 3rd.

N Engl J Med. 2012 Apr 12;366(15):1451; author reply 1451. doi: 10.1056/NEJMc1202104#SA1. No abstract available.

PMID:
22494136
16.

Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.

Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P.

Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):475-84. doi: 10.1586/erp.09.43.

PMID:
19817531
17.

Private expenditures on brand name prescription drugs after generic entry.

Balaban DY, Dhalla IA, Law MR, Bell CM.

Appl Health Econ Health Policy. 2013 Oct;11(5):523-9. doi: 10.1007/s40258-013-0052-y.

PMID:
23979876
18.

Switching statins: cost of simvastatin is overestimated.

Ashcroft JS.

BMJ. 2006 Jun 24;332(7556):1512. No abstract available.

19.

Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium.

Fraeyman J, Van Hal G, De Loof H, Remmen R, De Meyer GR, Beutels P.

Acta Clin Belg. 2012 May-Jun;67(3):160-71.

PMID:
22897063
20.

Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs.

Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A.

Expert Rev Pharmacoecon Outcomes Res. 2011 Feb;11(1):121-9. doi: 10.1586/erp.10.87.

PMID:
21351864

Supplemental Content

Support Center